NRG Oncology shared a post on LinkedIn:
“Press release: NRG Oncology Study Results Indicate that Radiation and Chemotherapy After Surgery Could be a Viable Alternative to Radical Cystectomy for Patients with Recurrent Bladder Cancer.”
Read further.
Source: NRG Oncology/LinkedIn
Douglas M. Dahl, MD, FACS, is the Chief of Urologic Oncology and a urologic surgeon at Massachusetts General Hospital. He specializes in the treatment of genitourinary cancers, minimally invasive surgical techniques, and related research. He serves as the Chief of the Division of Urologic Oncology, Clinical Co-Director of The Claire and John Bertucci Center for Genitourinary Cancers, and is also an Associate Urologist.